JP2016519650A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519650A5 JP2016519650A5 JP2016500767A JP2016500767A JP2016519650A5 JP 2016519650 A5 JP2016519650 A5 JP 2016519650A5 JP 2016500767 A JP2016500767 A JP 2016500767A JP 2016500767 A JP2016500767 A JP 2016500767A JP 2016519650 A5 JP2016519650 A5 JP 2016519650A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000027455 binding Effects 0.000 claims 41
- 239000000427 antigen Substances 0.000 claims 37
- 102000036639 antigens Human genes 0.000 claims 37
- 108091007433 antigens Proteins 0.000 claims 37
- 239000012634 fragment Substances 0.000 claims 37
- 101710169781 Gremlin-1 Proteins 0.000 claims 17
- 102100038367 Gremlin-1 Human genes 0.000 claims 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 238000000034 method Methods 0.000 claims 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 4
- 229960002897 heparin Drugs 0.000 claims 4
- 229920000669 heparin Polymers 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 4
- 206010016654 Fibrosis Diseases 0.000 claims 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 3
- 230000004761 fibrosis Effects 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 claims 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims 2
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000033115 angiogenesis Effects 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000024245 cell differentiation Effects 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 235000015872 dietary supplement Nutrition 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000009116 palliative therapy Methods 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 238000012286 ELISA Assay Methods 0.000 claims 1
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 claims 1
- 101001032872 Homo sapiens Gremlin-1 Proteins 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 206010029155 Nephropathy toxic Diseases 0.000 claims 1
- 206010061481 Renal injury Diseases 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000003510 anti-fibrotic effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 102000046318 human GREM1 Human genes 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 208000037806 kidney injury Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000009925 nephrosclerosis Diseases 0.000 claims 1
- 230000007694 nephrotoxicity Effects 0.000 claims 1
- 231100000417 nephrotoxicity Toxicity 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 230000009870 specific binding Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782874P | 2013-03-14 | 2013-03-14 | |
| US61/782,874 | 2013-03-14 | ||
| US201361883218P | 2013-09-27 | 2013-09-27 | |
| US61/883,218 | 2013-09-27 | ||
| PCT/US2014/021471 WO2014159010A1 (en) | 2013-03-14 | 2014-03-07 | Human antibodies to grem 1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019087970A Division JP2019151654A (ja) | 2013-03-14 | 2019-05-08 | ヒト抗ｇｒｅｍ１抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016519650A JP2016519650A (ja) | 2016-07-07 |
| JP2016519650A5 true JP2016519650A5 (enExample) | 2017-04-06 |
| JP6581075B2 JP6581075B2 (ja) | 2019-09-25 |
Family
ID=50390267
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016500767A Active JP6581075B2 (ja) | 2013-03-14 | 2014-03-07 | ヒト抗ｇｒｅｍ１抗体 |
| JP2019087970A Pending JP2019151654A (ja) | 2013-03-14 | 2019-05-08 | ヒト抗ｇｒｅｍ１抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019087970A Pending JP2019151654A (ja) | 2013-03-14 | 2019-05-08 | ヒト抗ｇｒｅｍ１抗体 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10377817B2 (enExample) |
| EP (1) | EP2970448B1 (enExample) |
| JP (2) | JP6581075B2 (enExample) |
| KR (1) | KR20150129718A (enExample) |
| CN (1) | CN105189548A (enExample) |
| AU (1) | AU2014241442B2 (enExample) |
| BR (1) | BR112015021979A2 (enExample) |
| CA (1) | CA2904644C (enExample) |
| CL (1) | CL2015002603A1 (enExample) |
| EA (1) | EA201591762A1 (enExample) |
| ES (1) | ES2898620T3 (enExample) |
| HK (1) | HK1220469A1 (enExample) |
| IL (1) | IL240769A0 (enExample) |
| MX (1) | MX369574B (enExample) |
| PH (1) | PH12015501865A1 (enExample) |
| SG (2) | SG10201707518YA (enExample) |
| WO (1) | WO2014159010A1 (enExample) |
| ZA (1) | ZA201506113B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6339063B2 (ja) * | 2012-03-15 | 2018-06-06 | エスエヌユー アールアンドディービー ファウンデーション | グレムリン−１に対する抗体 |
| MX369574B (es) | 2013-03-14 | 2019-11-13 | Regeneron Pharma | Anticuerpos humanos contra grem1. |
| AU2017252527A1 (en) | 2016-04-18 | 2018-11-08 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human CD40 and uses thereof |
| CN106399316B (zh) * | 2016-08-26 | 2019-03-01 | 西安交通大学第一附属医院 | 用于识别Gremlin-1的核酸适配子及其应用 |
| EP3504238A1 (en) * | 2016-08-29 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertension |
| WO2018112334A1 (en) | 2016-12-16 | 2018-06-21 | Bluefin Biomedicine, Inc. | Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof |
| GB201621635D0 (en) * | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
| CA3055305A1 (en) | 2017-03-22 | 2018-09-27 | Bluefin Biomedicine, Inc. | Anti-tmeff1 antibodies and antibody drug conjugates |
| WO2018175924A1 (en) * | 2017-03-24 | 2018-09-27 | The Broad Institute, Inc. | Methods and compositions for regulating innate lymphoid cell inflammatory responses |
| GB201802486D0 (en) * | 2018-02-15 | 2018-04-04 | Ucb Biopharma Sprl | Methods |
| JP7565219B2 (ja) | 2018-06-18 | 2024-10-10 | ユーシービー バイオファルマ エスアールエル | がんを予防及び治療するためのｇｒｅｍｌｉｎ－１アンタゴニスト |
| WO2020106461A2 (en) * | 2018-11-08 | 2020-05-28 | Celldex Therapeutics, Inc. | Anti-mertk antibodies and methods of use thereof |
| EP4061852A4 (en) * | 2019-11-21 | 2024-03-13 | Unity Biotechnology | ANTIBODIES AGAINST TIE-2 AND METHODS OF USE |
| EP4232475A1 (en) * | 2020-10-20 | 2023-08-30 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof |
| WO2022150654A2 (en) * | 2021-01-08 | 2022-07-14 | 10X Genomics, Inc. | Antigen-binding polypeptides specific for coronaviruses and uses thereof |
| US20240294622A1 (en) * | 2021-01-18 | 2024-09-05 | Suzhou Transcenta Therapeutics Co., Ltd. | Novel anti-gremlin1 antibodies |
| GB202205200D0 (en) | 2022-04-08 | 2022-05-25 | Ucb Biopharma Sprl | Combination with chemotherapy |
| GB202205203D0 (en) | 2022-04-08 | 2022-05-25 | UCB Biopharma SRL | Combination with inhibitor |
| EP4511395A1 (en) * | 2022-04-20 | 2025-02-26 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof |
| TW202409078A (zh) * | 2022-07-18 | 2024-03-01 | 中國大陸商蘇州創勝醫藥集團有限公司 | 穩定之包含抗gremlin1抗體的藥物製劑 |
| CN115786495A (zh) * | 2022-10-24 | 2023-03-14 | 杭州市第七人民医院 | 检测基因表达量的试剂在制备尼古丁加重的糖尿病肾病的筛查试剂盒中的用途 |
| WO2024213066A1 (en) * | 2023-04-13 | 2024-10-17 | Suzhou Transcenta Therapeutics Co., Ltd. | Combination therapies involving grem1 antagonists for treatment of cancer |
| CN117801109B (zh) * | 2024-03-01 | 2024-05-03 | 再少年(北京)生物科技有限公司 | iPS诱导定向分化成内皮祖细胞的方法及应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2437213A1 (fr) | 1978-09-28 | 1980-04-25 | Cm Ind | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
| AU6267098A (en) | 1997-02-05 | 1998-08-25 | Regents Of The University Of California, The | Morphogenic proteins |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6573096B1 (en) | 2000-04-01 | 2003-06-03 | The Research Foundation At State University Of New York | Compositions and methods for inhibition of cancer invasion and angiogenesis |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| RU2336902C2 (ru) | 2001-10-31 | 2008-10-27 | Алькон, Инк. | Морфогенные белки кости (вмр), рецепторы вмр и связывающие вмр белки и их применение для диагностики и лечения глаукомы |
| EP1777519A1 (en) | 2001-10-31 | 2007-04-25 | Alcon, Inc. | Bone morphogenic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ | Ｃｄ２０に対するヒトモノクローナル抗体 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| JP2008531525A (ja) | 2005-02-24 | 2008-08-14 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Ｖｉｉ因子ポリペプチド製剤を安定化する化合物 |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| US7411046B2 (en) | 2005-08-02 | 2008-08-12 | Arius Research Inc | Cancerous disease modifying antibodies |
| WO2007081751A2 (en) | 2006-01-05 | 2007-07-19 | The Johns Hopkins University | Compositions and methods for the treatment of cancer |
| US7420041B2 (en) | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| WO2007124486A2 (en) | 2006-04-21 | 2007-11-01 | Childrens Hospital Los Angeles | Bmp4 inhibitors |
| NZ573557A (en) | 2006-06-02 | 2010-08-27 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| US8383349B2 (en) | 2007-03-16 | 2013-02-26 | The Board Of Trustees Of The Leland Stanford Junior University | Bone morphogenetic protein antagonist and uses thereof |
| JP5410434B2 (ja) | 2007-09-28 | 2014-02-05 | バインド セラピューティックス インコーポレイテッド | ナノ粒子を用いた癌細胞の標的化 |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| SI2975051T1 (sl) | 2009-06-26 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom |
| JP6339063B2 (ja) * | 2012-03-15 | 2018-06-06 | エスエヌユー アールアンドディービー ファウンデーション | グレムリン−１に対する抗体 |
| MX369574B (es) | 2013-03-14 | 2019-11-13 | Regeneron Pharma | Anticuerpos humanos contra grem1. |
-
2014
- 2014-03-07 MX MX2015011616A patent/MX369574B/es active IP Right Grant
- 2014-03-07 JP JP2016500767A patent/JP6581075B2/ja active Active
- 2014-03-07 ES ES14713709T patent/ES2898620T3/es active Active
- 2014-03-07 HK HK16108451.7A patent/HK1220469A1/zh unknown
- 2014-03-07 BR BR112015021979A patent/BR112015021979A2/pt not_active Application Discontinuation
- 2014-03-07 WO PCT/US2014/021471 patent/WO2014159010A1/en not_active Ceased
- 2014-03-07 SG SG10201707518YA patent/SG10201707518YA/en unknown
- 2014-03-07 EP EP14713709.5A patent/EP2970448B1/en active Active
- 2014-03-07 US US14/775,637 patent/US10377817B2/en active Active
- 2014-03-07 EA EA201591762A patent/EA201591762A1/ru unknown
- 2014-03-07 CA CA2904644A patent/CA2904644C/en active Active
- 2014-03-07 SG SG11201506459PA patent/SG11201506459PA/en unknown
- 2014-03-07 CN CN201480014151.0A patent/CN105189548A/zh active Pending
- 2014-03-07 KR KR1020157024673A patent/KR20150129718A/ko not_active Withdrawn
- 2014-03-07 AU AU2014241442A patent/AU2014241442B2/en active Active
-
2015
- 2015-08-21 ZA ZA2015/06113A patent/ZA201506113B/en unknown
- 2015-08-23 IL IL240769A patent/IL240769A0/en unknown
- 2015-08-25 PH PH12015501865A patent/PH12015501865A1/en unknown
- 2015-09-11 CL CL2015002603A patent/CL2015002603A1/es unknown
-
2019
- 2019-05-08 JP JP2019087970A patent/JP2019151654A/ja active Pending
- 2019-06-27 US US16/454,663 patent/US11634480B2/en active Active
-
2023
- 2023-03-06 US US18/117,883 patent/US20230192831A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016519650A5 (enExample) | ||
| JP7440464B2 (ja) | 抗アクチビンａ抗体及びその使用 | |
| CN111133004B (zh) | 抗ctla-4抗体和其用途 | |
| CN106068275B (zh) | 抗pd-1的人抗体 | |
| JP2020514310A5 (enExample) | ||
| RU2012107286A (ru) | Высокоаффинные человеческие антитела к человеческому ангиопоэтину-2 | |
| CN114286828A (zh) | 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法 | |
| RU2010141584A (ru) | Антитело против csf-1r | |
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| JP2015514110A5 (enExample) | ||
| JP2017500018A5 (enExample) | ||
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| AU2021221287B2 (en) | Engineered anti-IL-2 antibodies | |
| HK1221409A1 (zh) | 抗ang2抗体和cd40激动剂的组合疗法 | |
| JP2015503909A5 (enExample) | ||
| CN102027015A (zh) | 抗cxcr4抗体 | |
| JP2018501254A5 (enExample) | ||
| AU2020247175A1 (en) | Treatment employing anti-IL-13R antibody or binding fragment thereof | |
| JP2008508858A (ja) | マクロファージ−刺激タンパク質受容体（ｒｏｎ）の阻害 | |
| JP2018529661A5 (enExample) | ||
| JP2018512402A5 (enExample) | ||
| CN107406502A (zh) | 结合血管生成素2的抗体与结合编程性死亡配体1的抗体的组合疗法 | |
| AU2015264550B2 (en) | Ang2 antibodies | |
| JP2018533588A (ja) | 治療パラダイム | |
| EP4305072A1 (en) | Antibodies against integrin heterodimers and uses thereof |